USFDA booster for Sun Pharma

K.S. Badri Narayanan | Updated on November 13, 2017

The stock of Sun Pharma is likely to witness buying interest as the company got permission from the US Federal Drug Administration for its Ultram ER tablets, a pain relieving drug. According to a notice issued to the BSE, the company has said that its subsidiary got an approval from the US authority for its abbreviated new drug application to market a generic version of Ultram ER, Tramadol hydrochloride extended release tablets. According to the company, Tramadol HCL ER tablets have annual sales of nearly $125 million in the US. Shares of Sun Pharma on Friday closed at Rs 512.40 on the BSE, down 1.19 per cent from its previous day close.

Published on December 11, 2011

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor